Published in Antimicrob Agents Chemother on August 01, 2002
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2006) 1.45
Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic Analysis. PLoS One (2016) 1.39
Inhibition of hepatitis B virus polymerase by entecavir. J Virol (2007) 1.32
The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol (2005) 1.29
Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cell. J Virol (2004) 1.14
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Review of hepatitis B therapeutics. Clin Infect Dis (2010) 1.06
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother (2007) 0.97
Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res (2008) 0.92
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine. Antimicrob Agents Chemother (2006) 0.87
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother (2008) 0.86
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One (2010) 0.86
Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int (2007) 0.81
Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol (2011) 0.81
Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases. Chem Res Toxicol (2011) 0.81
Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method. BMC Complement Altern Med (2013) 0.80
Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother (2013) 0.79
4'-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology (2015) 0.78
Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells. World J Gastroenterol (2008) 0.77
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis (2011) 0.76
Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med (2012) 0.75
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol (2009) 0.75
Early reduction of infected hepatocytes by activated immunity at the time of interferon withdrawal hepatitis followed by lamivudine administration resulted in higher seroconversion in hepatitis Be antigen-positive patients with chronic hepatitis B. J Gastroenterol (2006) 0.75
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J (1974) 14.12
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 4.14
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology (1996) 2.94
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet (1999) 2.40
Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA. Proc Natl Acad Sci U S A (1982) 2.20
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol (2001) 2.14
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology (1998) 2.01
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother (1997) 1.94
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS (1999) 1.78
Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J Virol (1995) 1.77
Lamivudine therapy of WHV-infected woodchucks. Virology (1998) 1.52
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis (2001) 1.46
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (1998) 1.45
Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology (1998) 1.41
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother (1998) 1.36
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 1.32
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother (1999) 1.27
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother (2002) 1.21
Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat (1999) 1.10
The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother (1998) 1.09
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Generation of replication-competent hepatitis B virus nucleocapsids in insect cells. J Virol (1998) 1.06
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother (2000) 0.98
The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. Br J Clin Pharmacol (2000) 0.89
The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res (2005) 12.94
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med (1999) 6.21
Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development (1995) 5.18
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
A unique RNA species involved in initiation of vesicular stomatitis virus RNA transcription in vitro. Cell (1976) 3.82
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
Many rhinovirus serotypes share the same cellular receptor. J Virol (1984) 3.59
Vesicular stomatitis virus: mode of transcription. J Gen Virol (1977) 3.53
Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol (1994) 3.46
Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A (2000) 3.41
Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension (1999) 3.33
Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc Natl Acad Sci U S A (2002) 3.29
Identification and characterization of genes that are required for the accelerated degradation of mRNAs containing a premature translational termination codon. Genes Dev (1995) 3.24
In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14. J Virol (1985) 3.19
Rapid Avr9- and Cf-9 -dependent activation of MAP kinases in tobacco cell cultures and leaves: convergence of resistance gene, elicitor, wound, and salicylate responses. Plant Cell (1999) 3.17
Patterns of smoking in Russia. Tob Control (1998) 3.17
Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. Proc Natl Acad Sci U S A (1985) 3.17
Animal models of Salmonella infections: enteritis versus typhoid fever. Microbes Infect (2001) 3.12
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1989) 3.09
The concepts of 'sameness' and 'difference' in an insect. Nature (2001) 3.08
DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res (2007) 3.07
Complete nucleotide sequence of the leader RNA synthesized in vitro by vesicular stomatitis virus. Cell (1978) 3.06
Honeybee navigation: nature and calibration of the "odometer". Science (2000) 3.06
Activation of a mitogen-activated protein kinase pathway is involved in disease resistance in tobacco. Proc Natl Acad Sci U S A (2001) 2.98
Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol (2012) 2.83
Assessing the impact of Cry1Ab-expressing corn pollen on monarch butterfly larvae in field studies. Proc Natl Acad Sci U S A (2001) 2.78
Cyanobacterial phycobilisomes. Characterization of the phycobilisomes of Synechococcus sp. 6301. J Biol Chem (1978) 2.73
Desensitization of AMPA receptors upon multiquantal neurotransmitter release. Neuron (1993) 2.70
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J Virol (2000) 2.65
Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology (1990) 2.64
Honeybee dances communicate distances measured by optic flow. Nature (2001) 2.61
The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. J Virol (1994) 2.61
Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet (1999) 2.60
Socioeconomic factors, material inequalities, and perceived control in self-rated health: cross-sectional data from seven post-communist countries. Soc Sci Med (2000) 2.57
Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol (1986) 2.54
The major and minor group receptor families contain all but one human rhinovirus serotype. Virology (1991) 2.50
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Nitric oxide and salicylic acid signaling in plant defense. Proc Natl Acad Sci U S A (2000) 2.47
Transmission/disequilibrium tests using multiple tightly linked markers. Am J Hum Genet (2000) 2.45
Comparisons of two methods for haplotype reconstruction and haplotype frequency estimation from population data. Am J Hum Genet (2001) 2.44
Xa21D encodes a receptor-like molecule with a leucine-rich repeat domain that determines race-specific recognition and is subject to adaptive evolution. Plant Cell (1998) 2.43
Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A (1999) 2.42
p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene (2001) 2.40
ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors. J Biol Chem (1984) 2.39
Alcohol consumption in a national sample of the Russian population. Addiction (1999) 2.33
Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med (1987) 2.30
Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway. Genes Dev (1997) 2.26
Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell (1996) 2.17
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
X-ray spectra estimation using attenuation measurements from 25 kVp to 18 MV. Med Phys (1999) 2.11
A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. Virology (1987) 2.10
Socioeconomic factors, perceived control and self-reported health in Russia. A cross-sectional survey. Soc Sci Med (1998) 2.09
Qualitative semi-parametric test for genetic associations in case-control designs under structured populations. Ann Hum Genet (2003) 2.07
alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet (2001) 2.07
14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J (2000) 2.06
Epidemiology of smoking in Ukraine, 2000. Prev Med (2001) 2.05
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol (1995) 2.05
Interaction of hydrolysis-resistant analogs of cyclic GMP with the phosphodiesterase and light-sensitive channel of retinal rod outer segments. Proc Natl Acad Sci U S A (1985) 2.04
Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem (1990) 1.99
Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell (1995) 1.99
Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther (1994) 1.95
Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development (2001) 1.95
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother (1997) 1.94
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax (2003) 1.93
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A (1996) 1.93
Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. J Biol Chem (1993) 1.92
Intervening polyadenylate sequences in RNA transcripts of vesicular stomatitis virus. Cell (1978) 1.92
RNA expression analysis using an antisense Bacillus subtilis genome array. J Bacteriol (2001) 1.89
Prevalence and determinants of smoking in Belarus: a national household survey, 2000. Eur J Epidemiol (2001) 1.89
Interferon induction of fibroblast proteins with guanylate binding activity. J Biol Chem (1983) 1.87
Differential dependence on GluR2 expression of three characteristic features of AMPA receptors. J Neurosci (1997) 1.86
Ribosome recycling by ribosome recycling factor (RRF)--an important but overlooked step of protein biosynthesis. Adv Biophys (1996) 1.86
Cloning, expression and characterization of a family 48 exocellulase, Cel48A, from Thermobifida fusca. Eur J Biochem (2000) 1.85
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Mapping and initiation studies on the leader RNA of vesicular stomatitis virus. Virology (1977) 1.78
Induction of unique mRNAs by human interferons. J Biol Chem (1982) 1.76
Clinical outcomes in reduction mammaplasty: a systematic review and meta-analysis of published studies. Mayo Clin Proc (2001) 1.74
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Direct measurement of AMPA receptor desensitization induced by glutamatergic synaptic transmission. J Neurosci (1996) 1.71
Expression and inheritance of multiple transgenes in rice plants. Nat Biotechnol (1998) 1.71
The structure of a "simple" phycobilisome. Ann Microbiol (Paris) (1983) 1.69
Isolation of a receptor protein involved in attachment of human rhinoviruses. J Virol (1986) 1.68
Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol (1986) 1.68
Evidence for in vivo ribosome recycling, the fourth step in protein biosynthesis. EMBO J (1998) 1.67
Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci (1998) 1.67
Roles of the catalytic domain and two cellulose binding domains of Thermomonospora fusca E4 in cellulose hydrolysis. J Bacteriol (1998) 1.65
Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst (2001) 1.65
Pathway-specific variants of AMPA receptors and their contribution to neuronal signaling. J Neurosci (1994) 1.65
Morphologic and molecular characterization of Salmonella typhimurium infection in neonatal calves. Vet Pathol (2002) 1.64
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother (2000) 1.59
Assessment of a DJ-1 (PARK7) polymorphism in Finnish PD. Neurology (2003) 1.59
[Correlation between gene expression of CCK-A receptor and gallbladder emptying in gallstone patients]. Zhonghua Wai Ke Za Zhi (1999) 1.56
Mucosal damage and recovery of the intestine after prolonged preservation and transplantation in dogs. Transplantation (2001) 1.55
Self-assembly of a beta-sheet protein governed by relief of electrostatic repulsion relative to van der Waals attraction. Biomacromolecules (2000) 1.54
Three-dimensional structure of the diphtheria toxin repressor in complex with divalent cation co-repressors. Structure (1995) 1.53